MAb directed to the thyroid microsomal antigen have been developed. All bound to 101-and 107-kD bands in Western blot analysis using thyroid microsomal fraction as antigen. The MAb also bound to microsomal proteins immunoprecipitated by serum from patients having a high titer of anti-microsomal antibody but no antibodies to thyroglobulin or thyrotropinstimulating hormone receptor. The pattern of binding was related to the amount of reducing agent. The 101-and 107-kD bands were increased by addition of dithiothreitol whereas, in its absence, numerous bands of higher molecular weight were present, suggesting a multimeric protein structure. Despite the inability to immunoprecipitate thyroid peroxidase (TPO) enzymatic activity, the MAb bound intensively in Western blot to denatured purified hog TPO and to denatured immunopurified human TPO. Trypsin digestion of the 101-107-kD antigen produced a doublet of 84-88 kD that was still immunoreactive with MAb. One of five polyclonal sera tested (with a microsomal antibody titer > I/20,480 measured by the tanned red cell hemagglutination technique) also recognized the 84-88-kD trypsin fragments. Addition of V8 protease led to a disappearance of the 107-kD protein, but not the 101-kD protein, proving that this antigen is formed by two different polypeptides. The MAb bound strongly to thyroid epithelium, whereas binding to papillary carcinoma was absent or low and moderate for follicular and Hurthle cell carcinoma.
Introduction
Antibodies against the human thyroid microsomal antigen (M antigen) are frequently present in autoimmune thyroid disease (AITD)' (1, 2) , and unlike other thyroid autoantibodies, fix complement, and thus may have a deleterious potential (3) . This M antigen has been described on the apical surface of human thyroid cells (4) and on a cloned rat cell line in vitro (5) . The nature of this antigen has been difficult to establish as it is not readily soluble, and is often contaminated with thyroglobulin (TG) (6) . We have previously identified the M antigen by immunoprecipitation and Western blot analysis using sera of patients with AITD (7, 8) . In reduced and denatured conditions, this antigen appears in Western blots as a doublet of 101-107 kD using antibody of patients with AITD. Similar findings have been described using immunoprecipitation (6, 9) . We speculated that there was a close intracellular relationship described between thyroid peroxidase (TPO) and M antigen, both of which are found in exocytotic vesicles, and we found antibodies in the sera of patients with AITD that could immunoprecipitate TPO enzymatic activity (10) , suggesting their possible identity. However, the loose correlation between titers of antibodies against M antigen by ELISA, and precipitation of TPO, suggested either that TPO and M antigen were different or that epitopes present in native TPO and in ELISA assays were not identical. Czarnocka et al. (1 1) have recently reported co-elution of TPO activity, and immunoreactivity measured by anti-microsomal antibodies from patients with AITD, from an immunoaffinity column prepared with MAb developed against thyroid membrane antigen. Other recent studies have reported MAb against crude thyroid microsomal proteins (12, 13) or purified peroxidase (14) , but none has taken as immunogen the specific microsomal antigen defined by polyclonal sera of patients with thyroid autoimmune disease. As SDS-PAGE allows precise localization of antigenic proteins identified previously by Western blot analysis, we developed MAb against the 107-kD antigenic band to better characterize the microsomal antigen itself and its relationship to TPO.
Methods
Antigen preparation. Human thyroid microsomes were prepared, using snap-frozen tissue from patients with Graves' disease, by differential centrifugation at 800, 10,000, and 104,000 g. The microsomal pellet was washed three times with PBS to remove soluble proteins (TG, hemoglobin, etc.) and stored at -70°C until used. Microsomes were heated 3 min in a boiling water bath in 18 mM Tris-HCl buffer, pH 6.8, containing 2.5% SDS, 2.25 M urea, and 5% mercaptoethanol, in addition to 10% glycerol and 0.002% bromophenol blue. The microsomal protein (3 mg/gel) was applied to SDS-PAGE based on the method of Victor et al. (15) . The proteins were electrophoresed in a 6% gel. After running, small vertical strips were cut in the middle and in the edges, while the other parts were kept in PBS at 4°C. The strips were used to detect proteins by Coomassie Blue R 250 and to detect the antigenic band by Western blot as previously described (7) . The antibodies were incubated 1 h and their binding was detected using a peroxidase-conjugated goat anti-human IgG (gamma chain-specific) (Cappel Laboratories, Cochranville, PA) in 25 mM Tris-HCl, 150 mM NaCl (TBS), 10% goat serum, and 0.05% Tween 20. The peroxidase substrate was 0.05% 3,3' diaminobenzidine (DAB) plus 0.3 mM H202 in TBS. This allowed localization of the 107-kD band, which was then cut out and electroeluted in a dialysis bag in 40 mM Tris plus 40 mM boric acid at pH 8.6, at 100 V for 3 h at 4°C. Polarity was then reversed for 2 min. The eluate was dialyzed against distilled water, lyophilized, and resuspended in a minimal volume of PBS.
Protein concentrations were determined by a modification of the method of Lowry et al. (16) .
Immunization. 6-8-wk-old female BALB/c mice were injected intraperitoneally with 50 ,g of gel-purified thyroid microsomal 107-kD protein in complete Freund's adjuvant. Every 4 wk the mice were injected with the same amount of protein in PBS until the sera were shown to have antibodies binding to the 107-kD protein by Western blot analysis, using a peroxidase-conjugated goat anti-mouse IgG plus IgM plus IgA. Animals with high serum titers received a booster injection of 20 ug antigen in sterile saline, intravenously, 3 wk after the last injection. 3 d later, the spleens were excised for fusion.
Cellfusion. Fusion was performed using polyethylene glycol (17) with some modifications (18) . Splenocytes were fused with SP2/O myeloma cells (19) . Selection ofhybridomas. After 10 to 21 d in culture, the clones were tested by dot-blot analysis and by Western blot analysis, since we found that sera from immunized mice bound in both conditions. In the dot-blot method, 5 ,g of briefly sonicated microsomal protein in 25 mM Tris-HCI plus 500 mM NaCl plus pH 7.4 were coated on 0.45-,uM nitrocellulose paper using a microfiltration apparatus (Bio-Rad Laboratories, Richmond, CA) according to the instructions ofthe company. Supernatant of growing hybrids was allowed to filter by gravity for 45 min. Bound antibodies were visualized using DAB after incubation with a 1:500 dilution of peroxidase-conjugated IgG fraction goat antimouse IgG plus IgM plus IgA (Cappel Laboratories). Positive hybrids were expanded and further tested by Western blot analysis. Thereafter, the positive hybrids were cloned two times by limiting dilution in the supernatant from a 3-d-old culture containing 1 X 10/ml irradiated (1,200 rad) Lewis rat thymocytes. Clones were expanded in 25-cm2 flasks or in vivo in the peritoneal cavities of tetramethylpentadecanetreated BALB/c female mice for the production of ascitic fluid. Monoclonal antibody was used from ascites fluid or after purification by MAPS-protein A kit (Bio-Rad Laboratories) and dialysis for 24 (a) . The preparation was tumbled overnight at 4°C and washed five times with TBS 0.5% NP-40. The immune complexes were eluted in sample treatment buffer and boiled 3 min before a 5-min centrifugation at 10,000 g at room temperature. The supernatant was then electrophoresed and electroblotted. After blocking with 5% dried skim milk the nitrocellulose sheet was cut into 5-mm wide strips and incubated with MAb (1:800 dilution of ascites fluid) against the 107-kD band. Bound antibodies were revealed by peroxidase-conjugated antibodies.
Immunoprecipitation of TPO by MAb. TPO was solubilized and used as previously described (10) . A dose-response relationship was first determined using normal mouse serum and ascites fluid developed by a nonspecific hybridoma. At 1:8 dilution of ascites or serum no nonspecific effect was observed. The MAb were then incubated overnight with the TPO preparation at 4°C before the addition of Pansorbin, which had previously been incubated with rabbit antimouse IgG and washed in TBS 0.5% NP-40. After a 5-min centrifugation, the supernatant was collected and assayed for peroxidase activity using the guaiacol method.
Immunohistochemical studies. Snap-frozen, 4-,MM cryostat sections of human tissues were incubated with MAb. The tissues studied included normal thyroid, colloid nodules, Graves' disease thyroid tissue, follicular, papillary, and Hurthle cell carcinomas, parathyroid, pancreas, stomach, skin, skeletal muscle, lymph node, spleen, and tonsil. Six MAb against the 107-kD band (1:2,500 dilution of ascites), one anti-TG MAb (1:100 dilution of culture supernatant), and KB-90 (1:10 dilution of stock) (Dako Corp., Santa Barbara, CA), which is a MAb directed against an epitope present in mononuclear phagocytes, were used in these studies. The sections were processed as described by Cordel et al. (20) . In Proteolysis ofthe microsomalfraction. The two enzymes used were trypsin, type III-S, from bovine pancreas (Sigma Chemical Co.) and protease, and Staphylococcus aureus V8 (Miles Scientific Div., Miles Laboratories). Solubilized microsomal fraction was incubated with 4 Mg of trypsin/ 100 Mg solubilized protein in a shaking waterbath for 30 min. The reaction was stopped by adding a fivefold excess of chromatographically purified soybean trypsin inhibitor (Sigma Chemical Co.). A control sample was treated similarly, but trypsin inhibitor was added before addition of trypsin. After electrophoresis the proteins were stained by Coomassie Blue and electroblotted before incubation with human polyclonal and MAb. In addition to control human sera, five MCHA (+) and TGHA (-) sera were used. Two ofthese were from patients with untreated Graves' disease, and three were from patients with Hashimoto's disease on thyroxine therapy.
Protease, S. aureus V8 was added in graded amounts (25, conditions (data not shown). To prove that the MAb were directed to the same protein as human anti-microsomal antibodies, the immunoprecipitate formed by a well-defined human serum (MCHA+, TGHA-, TRAb-) was electrophoresed and electroblotted onto nitrocellulose. Fig. 1 shows the binding of the six MAb to the immunoprecipitate of this serum, revealing the same 101-and 107-kD bands previously described. Control serum did not immunoprecipitate any immunoreactive protein. The same negativity was observed when using a fourfold increase in control serum, confirming the specificity of the immunoprecipitation by AITD serum.
A change in the binding of MAb was observed depending on the presence of reducing agent (21) . In nonreducing conditions, as shown in Fig. 2 A, MAb bound to several bands of higher molecular weight than the 101-107-kD bands. With increasing amounts of dithiothreitol, MAb bound mainly to 101-107-kD bands. When used at higher dilution, the MAb bound only to the fully reduced antigen as shown in Fig. 2 B. MAb to microsomal antigen bind to purified human and porcine TPO. MAb did not precipitate peroxidase activity. Fig.  3 shows the results of a typical experiment. The experiment was repeated four times. Increasing the amount of MAb and/ or second antibody, or decreasing the amount of TPO, had no specific effect. Purified MAb did not provide positive data. This is probably because our MAbs bind to a denatured antigen, and much less to a fully native antigen. As shown in Fig.  4 , five of the MAb bound on Western blot to highly purified hog TPO (22) Immunohistochemical studies. All MAb directed against the 101-107-kD bands bound specifically to thyroid tissue (Table I and Fig. 5) , and all of those MAb had the same pattern of binding. There was no staining of colloid, in contrast to the effect using antibody against TG. At 1:5,000 dilution ofascites fluid, the staining was predominantly at the apical border of the cells, using Graves' disease thyroid and colloid nodule tissues. At lower dilution the thyroid cell cytoplasm appeared homogeneously positive. Binding to thyroid carcinoma was variable. In follicular carcinomas MAb directed against the 107-kD protein bound strongly, to about the same extent as to colloid nodules. In the papillary carcinomas tested the expression of the microsomal antigen was absent or very faint. In Hurthle cell carcinoma these MAb bound, but not as intensely as to follicular carcinoma. MAb to TG bound strongly to tumorous and nontumorous thyroid tissue, and no obvious difference was observed between the different carcinomas.
Identification ofepitopes by partial antigen proteolysis. We studied the ability of the MAb and sera from patients with AITD to bind to peptide fragments of the microsomal antigen after digestion with enzymes. Incubation with V8 protease led to a loss of the 107-kD band as seen by Coomassie Blue staining and binding of both monoclonal and human antibodies (Fig. 6) . A moderate decrease of the antigenicity ofthe 10 l-kD band was observed. Additional antigenic fragments were detected by the MAb, implying that these antibodies are not directed against the same antigenic sites as the polyvalent AITD antibodies studied, or that the epitopes recognized are of minor importance in most human polyvalent antiserum. In contrast, digestion by trypsin led to a total loss of the 101-and 107-kD bands, and created two contiguous bands of 84 and 88 kD, which were detected by MAb (Fig. 7 A) . Most polyclonal sera, including serum from patient c, which bound to the 101-107-kD proteins (Fig. 6 A) , showed no binding to the trypsinized antigen. One sera bound strongly to the new form of antigen (Fig. 7 E) . There was thus a major difference in the pattern of recognition of antigen by different human antibodies. Some serum, despite strong binding to microsomal antigen by hemagglutination test, ELISA, and immunoprecipitation, did not bind to the denatured and reduced microsomal antigen. Other sera, while binding to the 107-kD protein, did not bind to the trypsinized protein.
Only one of the sera tested bound to the same extent to the two forms of the antigen.
Discussion
Six MAb to the human microsomal antigen have been produced and characterized with respect to affinities and binding to various conditions of this antigen, and by binding to TPO and human tissues. These MAb, derived by immunization with a well-defined microsomal antigen, provide evidence that the microsomal antigen and the TPO are identical.
All MAb showed specific binding to thyroid microsomal proteins; no crossreactivity was identified (23 101-and 107-kD bands when crude microsomal fraction or thyroid microsomal proteins immunoprecipitated by a MCHA (+) serum were run on SDS-PAGE. The characteristics of binding of MAb suggest that the microsomal antigen, in denaturing and reducing conditions, consists solely of 101-and 107-kD bands (8) . We consistently found two antigenic bands, using either microsomal fraction (with/without trypsin) as immunopurified TPO. The pattern of binding to large-size proteins may be due to a nonspecific interaction of sulfhydryl groups to other proteins (21) , or may indicate that, in its more native form, the antigen is of high molecular weight and is composed of subunits. The lack of immunoprecipitation of TPO enzymatic activity by the MAb is certainly related to the mode of immunization, in which the antigen is fully denatured and reduced. This led us to look at the binding to that purified protein. Five of the six MAb bound on Western blot strongly to highly purified porcine TPO, and all six bound to immunopurified human TPO. It is not known if the similarity of binding is related to a common epitope recognized by the various MAb. These results provide further proof that thyroid microsomal antigen and peroxidase are identical proteins (1-1, 14) .
The binding to both cytoplasm and apical surface of thyrocytes confirm previous studies using MAb (13) and polyclonal antibodies (24) , implying that the "microsomal" and "microvillar" antigen are similar. Unlike MAb to TG, the MAb against the microsomal antigen showed a variability in binding to various histologic types of carcinomas. The TSH receptor is not always functional in these tumors; the mechanisms leading to carcinogenesis may not be the same in the different cancers; and various oncogenes (25) (27) that trypsinization ofthe microsomal antigen led to a 75% decrease of antigenicity. Mariotti et al. (28) described a loss of microsomal antigenicity after such treatment, using an iodinated IgG. As one patient's serum was used, the data of that study have to be considered cautiously. In contrast, trypsinization of peroxidase is a useful step in preparation of TPO (29) . Our (31) and human TPO (32) B of the antigen may be useful in studying the binding of polyclonal antibodies and correlation with the clinical course ofthe autoimmune process.
